• About Us
  • Contact us
0
0
Book an Appointment
Home
Products
Cardiovascular Pharmacogenomic (PGx) Panel
Cardiovascular Pharmacogenomic (PGx) Panel

Cardiovascular Pharmacogenomic (PGx) Panel

Turnaround Time: 10-14 days

Genes:  APOE, CYP2C19, CYP2C9, CYP2D6, CYP3A4, SLCO1B1, VKORC1.

Overview

Includes genes associated with drug metabolism with high-level evidence and clinically actionable guidelines. Our Cardiovascular Pharmacogenomic (PGx) Panel is designed to provide a complete genetic profile of how your body processes and responds to medications across cardiology specialty. By identifying gene–drug interactions, this test helps your healthcare provider choose the right medication and dosage for you, reducing side effects and improving treatment success. The panel evaluates genes involved in drug metabolism, transport, and receptor activity for cardiovascular medications. The results help guide selection, dosing, and monitoring of cardiovascular drugs to improve efficacy and reduce adverse events.

$199.00

What’s in Your Kit

  • 1 sterile cheek swabs
  • Secure collection tube
  • Detailed step-by-step instructions
  • Prepaid return shipping envelope
  • Patient consent form
  • Patient requsition form
  • Biohazard bag

Collection Instructions

Simple cheek swab (non-invasive, no needles required)

Avoid eating, drinking, smoking, or chewing gum for 30 minutes before collection

Pharmacogenics Specimen Collection Device

Let patient rinse mouth with clean water prior to the sample collection. Ensure patient does NOT eat, drink, smokeor chew tobacco, and chem gum for 30 minutes before collection specimen.

Label the outside of collection device patient’s Full Name, DOB, Date of Collection.

Open package and remove dry swab without touching sponge tip.

Place sponge tip as far back in the mouth and press firmly along the lower gums going up and down motion( against the inside of one cheek) . Use astopwatch to time the collection for at least 60 seconds per swab to collect cells. It is important to collect samples from maximum mucosal surfaces. If possible, avoid rubbing teeth.

Gently repeat step 4 on the opposite side of the cheek along the lower gums for additional 60 seconds.

Remove the swab from patient mouth and return the swab to the original specimen collection device containerand close the lid tightly.

Sample Final Report

  • Gene-by-gene analysis
  • Actionable recommendations for your provider
  • Medication list sorted by “Use as Directed,” “Use with Caution,” or “Consider Alternatives”
  • Educational notes for patients
  • Your response to hundreds of prescription medications
  • Individualized medication dosing guidelines
  • Personalized gene drug interactions

Medications and disease categories Covered

Over 27 medications across multiple therapeutic classes, including:
  • Cardiovascular: Blood thinners, statins, beta blockers, antiarrhythmics, cholesterol medications

Benefits Of Testing

  • Improved drug efficacy

  • Reduced risk of adverse drug reactions (ADRs)

  • Personalized dosing strategies

  • Guidance for alternative therapy selection

Texas Diagnostics laboratories Medication Directory Filter through the list of medications and find yours
Category Therapeutic Class Generic Name Trade Name(s) Gene evidence level
Cardiovascular x x x APOE Informative
Cardiovascular Antiplatelets Clopidogrel Plavix CYP2C19 Actionable
Cardiovascular Cardiac myosin inhibitor Mavacamten Camzyos CYP2C19 Actionable
Cardiovascular Angiotensin II Receptor Antagonists Azilsartan Edarbi, Edarbyclor CYP2C9 Informative
Cardiovascular Statins Fluvastatin Lescol CYP2C9 Informative
Cardiovascular Angiotensin II Receptor Antagonists Irbesartan Avapro CYP2C9 Informative
Cardiovascular Angiotensin II Receptor Antagonists Losartan Cozaar, Hyzaar CYP2C9 Informative
Cardiovascular Diuretics Torsemide Demadex CYP2C9 Informative
Cardiovascular Anticoagulants Warfarin Coumadin CYP2C9 Actionable
Cardiovascular Beta Blockers Carvedilol Coreg, Coreg CR CYP2D6 Actionable
Cardiovascular Antiarrhythmics Flecainide Tambocor CYP2D6 Actionable
Cardiovascular Beta Blockers Metoprolol Lopressor CYP2D6 Actionable
Cardiovascular Antiarrhythmics Mexiletine Mexitil CYP2D6 Actionable
Cardiovascular Beta Blockers Nebivolol Bystolic CYP2D6 Actionable
Cardiovascular Antiarrhythmics Propafenone Rythmol CYP2D6 Actionable
Cardiovascular Beta Blockers Propranolol Inderal CYP2D6 Actionable
Cardiovascular Antianginal Agents Ranolazine Ranexa CYP2D6 Actionable
Cardiovascular Beta Blockers Timolol Blocadren CYP2D6 Informative
Cardiovascular Statins Atorvastatin Lipitor CYP3A4 Informative
Cardiovascular Statins Lovastatin Mevacor, Altoprev, Advicor CYP3A4 Informative
Cardiovascular Statins Atorvastatin Lipitor SLCO1B1 Actionable
Cardiovascular Statins Fluvastatin Lescol SLCO1B1 Informative
Cardiovascular Statins Lovastatin Mevacor, Altoprev, Advicor SLCO1B1 Informative
Cardiovascular Statins Pitavastatin Livalo SLCO1B1 Informative
Cardiovascular Statins Pravastatin Pravachol SLCO1B1 Informative
Cardiovascular Statins Rosuvastatin Crestor SLCO1B1 Informative
Cardiovascular Statins Simvastatin Zocor SLCO1B1 Actionable
Cardiovascular Anticoagulants Warfarin Coumadin VKORC1 Actionable
  Test Limitations:
  • Results do not imply that there are no other contributors, genetic or otherwise, to this individual’s phenotype, and  do not rule out a genetic cause for the indication for testing. Annotations for FDA, PharmGKB, and CPIC guidelines are updated regularly. Official gene names change over time. Result interpretation is based on the available clinical and family history information for this individual, collected published information, and Alamut annotation available at the time of reporting. This assay is designed and validated for detection of germline variants only. Analysis and reporting is limited to the diplotypes/markers explicitly listed on this report. This test cannot rule out the possibility that the tested individual has a rare or uncharacterized phenotype for genes on this panel.
  • Not a diagnostic test – It does not diagnose disease or predict all possible drug responses.
  • Variant coverage – Only the variants included on the panel will be reported; other genetic factors affecting drug response may not be assessed.
  • Non-genetic influences – Age, liver/kidney function, other medications, diet, and lifestyle can also affect drug metabolism and efficacy.
  • Ethnic variability – Test performance and interpretation may vary based on ancestry due to differences in variant prevalence.
  • Sample quality – Poor sample collection can lead to incomplete or inconclusive results.
  • Ongoing research – Pharmacogenomic science evolves; interpretation may change as new evidence emerges.
  • Targets are carefully selected based on established gene–drug interaction evidence from CPIC, PharmGKB, and FDA labeling.
  • A “normal metabolizer” result does not guarantee effectiveness or eliminate the risk of side effects.
  • Results should be interpreted in conjunction with clinical findings and other laboratory data; they are not intended as the sole basis for therapy decisions.
  • This test does not provide information on non-cardiovascular medications.
No products in the cart.